Abraxane, developed using nab technology platform, is a solvent-free chemotherapy treatment option for metastatic breast cancer.
The study comprised evaluation of Abraxane in combination with gemcitabine in 67 patients.
Abraxane with gemcitabine demonstrated a median overall survival of 12.2 months
The levels of secreted protein acidic and rich in crysteine (SPARC) were evaluated in 36 patients and patients with high-SPARC biomarker achieved higher overall survival.
The data is published in Journal of Clinical Oncology Online.